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We do not claim our article to be the fi rst evidence that circulating microRNAs (miRNAs) have potential as breast cancer biomarkers, and we acknowledge that other groups such as theirs are working on this exciting new area (for example, [3] ). However, we think that our data on the association with breast tumor progression are novel.
Th e fi nding that total RNA levels were higher in M0 patients than in controls and M1 breast cancer patients cannot exclusively refl ect the quality of our used RNA extraction technique because the diff erence in the concentrations was signifi cant, and we used the same technique for all groups. When we quantifi ed the RNA concentrations using the mirVana PARIS kit (Ambion) and the Trizol® extraction (Invitrogen), we found the RNA amounts diff ered considerably, but the relative changes in the RNA levels of the diff erent groups showed the same tendency. Th e fact that whole blood contains higher RNA amounts than serum/plasma is an un disputable matter. However, we intended to measure the amounts of cell-free RNA.
In our article we discussed that the lower total RNA levels in patients with metastatic disease compared to M0 patients might be explained in part by the diff erent tissue sources (for example, primary tumor, circulating tumor cells and mononuclear cells) from which the bulk of RNA in blood may come. Th e claim that total RNA concentration indicated tumor progression alludes to the higher total RNA levels detected in the more advanced tumor stages within the M0 subgroup.
We selected our miRNA panel from a large number of existing miRNAs because these miRNAs target mRNAs crucial in breast cancer progression (for example, epithelial-mesenchymal transition). Certainly, there are other miRNAs strongly associated with breast cancer.
We agree that the pre-operative analysis of blood should be more informative for cancer detection, whereas the post-operative analysis might be more valuable to estimate tumor progression. Our small pilot study on sera from 10 patients revealed similar levels before and about 4 weeks after surgery (P = 0.375); however, this aspect needs to be revisited with a larger cohort of patients.
Abbreviations miRNA, microRNA.
